Preclinical evaluation of HIV-1 envelope immunogens in humanized mice

HIV-1包膜免疫原在人源化小鼠中的临床前评估

• 批准号: 10667351
• 负责人: VIKRAM SRIVASTAVA
• 金额: $ 30万
• 依托单位: NEOVAXSYN, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10667351
• 关键词: Animal Model; Antibodies; Antibody Response; Antigens; Development; Formulation; Generations; Genes; Genetically Engineered Mouse; Goals; HIV; HIV vaccine; HIV-1; Human; Immunoglobulins; Peptides; Phase I Clinical Trials; Preclinical Testing; Testing; Transgenic Mice; humanized mouse; innovation; neutralizing antibody; novel; preclinical evaluation; programs; vaccine candidate; vaccine strategy

Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates: The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focused on developing and evaluating innovative platforms and formulations of HIV envelope (Env) immunogens for the induction and generation of a durable and broadly neutralizing antibody (bNAb) response. The goal of this program is to utilize genetically engineered mouse models, such as human immunoglobulin KI or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.

用于HIV候选疫苗临床前评价的基因工程小鼠：新型HIV候选疫苗的开发通常需要在动物模型中进行临床前试验，然后再进行I期临床试验。多种努力集中在开发和评估用于诱导和产生持久和广泛中和抗体（bNAb）应答的HIV包膜（Env）免疫原的创新平台和制剂上。该计划的目标是利用基因工程小鼠模型，如人免疫球蛋白KI或其他表达相关人类基因的转基因小鼠，以加速HIV候选疫苗的测试和开发。